Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Delmas, P.D. et al.

Pierre D. Delmas, Bernard Vrijens, Richard Eastell, Christian Roux, Huibert A. P. Pols, Johann D. Ringe, Andreas Grauer, David Cahall, Nelson B. Watts,

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

CONTEXT: Persistence with osteoporosis treatment is poor but is important for maximum benefit. OBJECTIVE: The objective of the study was to assess the impact of physician reinforcement using bone turnover markers (BTMs) on persistence with risedronate treatment. DESIGN AND SETTING: This was a 1-yr multinational prospective, open-label, blinded study in 171 osteoporosis centers in 21 countries. PATIENTS: A total of 2382 postmenopausal women (65-80 yr old) with spine/hip T-score -2.5 or less or T-score -1.0 or less with a low-trauma fracture. INTERVENTION: Intervention included calcium 500 mg/d, vitamin D 400 IU/d, and risedronate 5 mg/d for 1 yr. Centers were randomized to reinforcement (RE+) or no reinforcement (RE-). At 13 and 25 wk, reinforcement based on urinary N-telopeptide of type I collagen change from baseline was provided to the RE+ patients using the following response categories: good (>30% decrease), stable (-30% to +30% change), or poor (>30% increase). MAIN OUTCOME MEASURES: Persistence assessed with electronic drug monitors was measured. RESULTS: In the overall efficacy population (n=2302), persistence was unexpectedly high and was similar for both groups (RE-, 77%; RE+, 80%; P=0.160). A significant relationship between the type of message and persistence was observed (P=0.017). Compared with RE-, intervention based on a good BTM response was associated with a significant improvement in persistence [hazard ratio (HR) 0.71; 95% confidence interval (CI) 0.53-0.95]. Persistence was unchanged (HR 1.02; 95% CI 0.74-1.40) or lower (HR 2.22; 95% CI 1.27-3.89) when reinforcement was based on a stable or poor BTM response, respectively. Reinforcement was associated with a lower incidence of new radiologically determined vertebral fractures (odds ratio 0.4; 95% CI, 0.2-1.0). CONCLUSIONS: Reinforcement using BTMs influences persistence with treatment in postmenopausal women with osteoporosis, depending on the BTM response observed.[1]

References

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. Delmas, P.D., Vrijens, B., Eastell, R., Roux, C., Pols, H.A., Ringe, J.D., Grauer, A., Cahall, D., Watts, N.B. J. Clin. Endocrinol. Metab. (2007) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.